Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis.

Pharmacogenomics - 1 Jan 2017

Prieto-Pérez Rocío, Llamas-Velasco Mar, Cabaleiro Teresa, Solano-López Guillermo, Márquez Beatriz, Román Manuel, Ochoa Dolores, Talegón María, Daudén Esteban, Abad-Santos Francisco

Abstract excerpt

Aim/Materials & methods: Few studies have evaluated the influence of pharmacogenetics in psoriatic patients treated with ustekinumab. We evaluated 121 polymorphisms to study a possible association between these SNPs and the response to ustekinumab (PASI75 at 4 months; n = 69). RESULTS/CONCLUSION: The adjusted results (false discovery rate) showed an association between five SNPs in TNFRSF1A, HTR2A, NFKBIA, ADAM33...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dermatologic Agents
Share to ADAM33 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to NFKBIA gene

Share to STAT4 gene

Share to Pharmacogenetics

Share to Polymorphism, Single Nucleotide

Share to Psoriasis

Share to Severity of Illness Index

Source

Identifiers

PMID: 27977334
DOI: 10.2217/pgs-2016-0122

Genes

ADAM33
CHUK
NFKBIA
STAT4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis.PMID 27977334Read ↗

Pharmacogenetics Update on Biologic Therapy in PsoriasisSemantic proximity Read ↗

New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis.Semantic proximity Read ↗

Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis.Semantic proximity Read ↗

Pharmacogenetic Analysis of Variants in IL-6 Signaling and Response to Modern Therapeutic Approaches in Greek Patients with Atopic Dermatitis.Semantic proximity Read ↗

IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis.Semantic proximity Read ↗

Pharmacogenomics on the Treatment Response in Patients with Psoriasis: An Updated ReviewSemantic proximity Read ↗

Influence of Genetic Polymorphisms on Response to Biologics in Moderate-to-Severe PsoriasisSemantic proximity Read ↗

A Pharmacogenetic Study of Psoriasis Risk Variants in a Greek Population and Prediction of Responses to Anti-TNF-α and Anti-IL-12/23 Agents.Semantic proximity Read ↗

Pharmacogenetics of psoriasis:<i>HLA-Cw6</i>but not<i>LCE3B/3C</i>deletion nor<i>TNFAIP3</i>polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumabSemantic proximity Read ↗

Genetics of Psoriasis and Pharmacogenetics of Biological DrugsSemantic proximity Read ↗

Pharmacogenetic markers to predict the clinical response to methotrexate in south Indian Tamil patients with psoriasis.Semantic proximity Read ↗

Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.